An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Alina Volkova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Modeling and Simulation Decisions FZ - LLC, Dubai, UAE. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Interferon Type I, Inflammation, Models, Biological. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Modeling and Simulation Decisions FZ - LLC, Dubai, UAE.
- Marchuk Institute of Numerical Mathematics of the Russian Academy of Sciences, Moscow, Russia.
- Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Cambridge, UK.
- Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Gaithersburg, Maryland, USA.
- Research Center of Model-Informed Drug Development, Sechenov First Moscow State Medical University, Moscow, Russia.
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
ORCID-Profile: Alina Volkova, Victor Sokolov, Florencia Tettamanti, Meghna Verma, Yaroslav Ugolkov, Kirill Peskov, Weifeng Tang, Holly Kimko
Zitieren
APA
Volkova, A., Sokolov, V., Tettamanti, F., Verma, M., Ugolkov, Y., Peskov, K., Tang, W., & Kimko, H. (2025). An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70043
Vancouver
Volkova A, Sokolov V, Tettamanti F, Verma M, Ugolkov Y, Peskov K, et al. An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70043
BibTeX
@article{Volkova2025,
author = {Volkova, Alina and Sokolov, Victor and Tettamanti, Florencia and Verma, Meghna and Ugolkov, Yaroslav and Peskov, Kirill and Tang, Weifeng and Kimko, Holly},
title = {An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70043}
}
EUVIMED